| 2022-11-19 |
复牌提示：
2022-11-18 19:55:00 停牌，复牌日期 2022-11-22 00:00:01
|
| 2022-11-04 |
详情>>
股本变动：
变动后总股本4941.74万股
|
| 2022-11-04 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.72美元,归母净利润-8208.8万美元,同比去年增长31.79%
|
| 2022-10-07 |
股东大会：
将于2022-11-17召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated August 22, 2022 (such agreement, as it may be amended, modified, or supplemented from time to time, the “Merger Agreement”), by and among Alcon Research, LLC, a Delaware limited liability company (“Alcon”), Lyon Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon (“Merger Sub”), and Aerie. Upon the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into Aerie, with Aerie continuing as the surviving corporation and a wholly owned subsidiary of Alcon (the “Merger”).
2.To consider and vote on the proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid or become payable to Aerie’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the proposal to adopt the Merger Agreement if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting (the “Adjournment Proposal”).
|
| 2022-08-05 |
详情>>
业绩披露：
2022年中报每股收益-1.16美元,归母净利润-5526.2万美元,同比去年增长31.48%
|
| 2022-08-04 |
财报披露：
美东时间 2022-08-04 盘后发布财报
|
| 2022-05-06 |
详情>>
业绩披露：
2022年一季报每股收益-0.76美元,归母净利润-3589.1万美元,同比去年增长14.47%
|
| 2022-04-26 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
2.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.Conduct an advisory vote to approve compensation for our named executive officers (“say-on-pay”);
4.Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2022-02-25 |
详情>>
业绩披露：
2019年年报每股收益-4.39美元,归母净利润-2亿美元,同比去年增长14.18%
|
| 2022-02-25 |
详情>>
业绩披露：
2021年年报每股收益-1.61美元,归母净利润-7481万美元,同比去年增长59.14%
|
| 2021-11-05 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-2.6美元,归母净利润-1.2亿美元,同比去年增长12.14%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-1.75美元,归母净利润-8065.2万美元,同比去年增长17.12%
|
| 2021-08-05 |
详情>>
业绩披露：
2020年中报每股收益-2.12美元,归母净利润-9731.6万美元,同比去年增长-2.31%
|
| 2021-05-06 |
详情>>
业绩披露：
2021年一季报每股收益-0.91美元,归母净利润-4196.4万美元,同比去年增长14.58%
|
| 2021-04-27 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
2.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.Conduct an advisory vote to approve compensation for our named executive officers (“say-on-pay”);
4.Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2021-02-26 |
详情>>
业绩披露：
2020年年报每股收益-3.99美元,归母净利润-1.83亿美元,同比去年增长8.26%
|
| 2020-11-06 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-2.99美元,归母净利润-1.37亿美元,同比去年增长5.23%
|
| 2020-04-24 |
股东大会：
将于2020-06-11召开股东大会
会议内容 ▼▲
- 1.Election of the three nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
2.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.Conduct an advisory vote to approve compensation for our named executive officers (“say-on-pay”);
4.Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2019-04-10 |
股东大会：
将于2019-05-23召开股东大会
会议内容 ▼▲
- 1.Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
2.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.Conduct an advisory vote to approve compensation for our named executive officers (“say-on-pay”);
4.Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2018-07-02 |
详情>>
内部人交易：
Kopczynski Casey C.共交易2笔
|
| 2018-04-27 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- (1)Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
(2)Amendment and restatement of the Aerie Pharmaceuticals, Inc. Amended and Restated Omnibus Incentive Plan as the Aerie Pharmaceuticals, Inc. Second Amended and Restated Omnibus Incentive Plan to increase the number of shares issuable under the plan by 4,500,000;
(3)Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
(4)Conduct an advisory vote to approve compensation for our named executive officers (“say-on-pay”);
(5)Conduct an advisory vote on the frequency of future advisory votes to approve compensation for our named executive officers (“say-on-frequency”);
(6)Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2017-04-27 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- (1)Election of the three nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
(2)Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
(3)Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1. Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term, or until their successors are duly elected and qualified;
2. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2015-02-27 |
股东大会：
将于2015-04-10召开股东大会
会议内容 ▼▲
- 1.Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term;
2.Approval of the Aerie Pharmaceuticals, Inc. Amended and Restated Omnibus Incentive Plan;
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
4.Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|
| 2014-04-30 |
股东大会：
将于2014-06-11召开股东大会
会议内容 ▼▲
- 1. Election of the two nominees named in the attached proxy statement as Directors to serve on the Board of Directors for a three-year term;
2. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
3. Consideration of any other business properly brought before the meeting and any adjournment or postponement thereof.
|